Fredj G, Barbier M, Kalifa D, Dietlin F, Bonhomme L, Maurisson G; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 200 (abstract no. S.B.458).
Hopital P. Brousse Villejuif, Paris (France)
OBJECTIVE: Evaluation of survival rate, clinical and serological status in patients treated with THA after discontinuation of AZT treatment for intolerance. METHODS: 15 patients (2 females- 13 males) with stage IV HIV infection (IVC 1:9 pts, IVA:2 pts; IVD:4pts) were treated with AZT (600-1200 mg/day). Due to medullar toxicity, AZT had to be discontinued after 25 +/- 9 weeks (range 12-50) of treatment. Within one month after discontinuation of AZT the patients were treated by THA (150-250 mg/day). RESULTS: The mean duration of THA treatment was 18 weeks (range 8-42 weeks). In table above, the results are expressed as mean variation (%) after treatment (Dt) in comparison with absolute values at Do. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: Patients already treated with AZT have no alternative treatment after discontinuation of AZT for medullar toxicity. Despite the fact that there is no control group, THA treatment yields encouraging results which should be confirmed.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Female
- HIV Infections
- HIV Seropositivity
- Humans
- Male
- Tacrine
- Zidovudine
Other ID:
UI: 102196271
From Meeting Abstracts